Shares in Genmab A/S gained as much as 13 percent during trading Tuesday following the release of additional clinical data on Arzerra (ofatumumab), an anti-CD20 monoclonal antibody undergoing a Phase III trial in patients with refractory chronic lymphocytic leukemia (CLL). (BioWorld International)